home / stock / imab / imab short
Short Information | I-MAB (NASDAQ:IMAB)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 786,316 |
Total Actual Volume | 3,883,637 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 39,316 |
Average Short Percentage | 19.56% |
Is there a IMAB Short Squeeze or Breakout about to happen?
See the IMAB Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $1.56 | $1.5 | $1.609 | $1.5 | 148,522 | 28,778 | 19.38% |
07-02-2024 | $1.61 | $1.58 | $1.63 | $1.57 | 147,129 | 44,518 | 30.26% |
07-01-2024 | $1.67 | $1.62 | $1.67 | $1.59 | 103,149 | 21,672 | 21.01% |
06-28-2024 | $1.71 | $1.67 | $1.7334 | $1.6 | 110,690 | 9,842 | 8.89% |
06-27-2024 | $1.72 | $1.69 | $1.7694 | $1.66 | 99,601 | 12,521 | 12.57% |
06-26-2024 | $1.7 | $1.705 | $1.76 | $1.68 | 163,140 | 41,666 | 25.54% |
06-25-2024 | $1.71 | $1.72 | $1.74 | $1.6906 | 54,741 | 6,280 | 11.47% |
06-24-2024 | $1.67 | $1.72 | $1.73 | $1.67 | 85,140 | 14,585 | 17.13% |
06-21-2024 | $1.71 | $1.68 | $1.72 | $1.68 | 95,766 | 13,784 | 14.39% |
06-20-2024 | $1.76 | $1.69 | $1.775 | $1.67 | 187,773 | 42,355 | 22.56% |
06-18-2024 | $1.8 | $1.77 | $1.81 | $1.76 | 150,203 | 25,066 | 16.69% |
06-17-2024 | $1.82 | $1.82 | $1.84 | $1.77 | 145,856 | 44,794 | 30.71% |
06-14-2024 | $1.85 | $1.84 | $1.86 | $1.83 | 98,437 | 21,010 | 21.34% |
06-13-2024 | $1.84 | $1.86 | $1.86 | $1.84 | 63,884 | 18,201 | 28.49% |
06-12-2024 | $1.87 | $1.85 | $1.87 | $1.83 | 222,343 | 29,155 | 13.11% |
06-11-2024 | $1.84 | $1.86 | $1.89 | $1.84 | 132,787 | 25,184 | 18.97% |
06-10-2024 | $1.91 | $1.855 | $1.91 | $1.84 | 182,113 | 25,741 | 14.13% |
06-07-2024 | $1.88 | $1.88 | $1.9 | $1.83 | 256,372 | 68,131 | 26.58% |
06-06-2024 | $1.91 | $1.87 | $1.93 | $1.82 | 372,022 | 59,979 | 16.12% |
06-05-2024 | $1.98 | $1.9 | $2 | $1.72 | 1,063,969 | 233,054 | 21.9% |
News, Short Squeeze, Breakout and More Instantly...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...
Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be...